newsfilter
← Latest News
GlobeNewswire·

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC